Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Positive
- None.
Negative
- None.
News Market Reaction – DNA
In the Jan 13 session, DNA gained 0.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | ARPA-H partnership | Positive | +8.5% | ARPA-H backed POSEIDON oncology screening partnership with Carnegie Mellon. |
| Dec 17 | Manufacturing collaboration | Positive | -0.2% | Collaboration with Agricen to optimize fermentation for soil amendment product. |
| Dec 09 | Drug safety platform | Positive | +1.7% | ARPA-H funded PREDICTS drug safety data platform with Deep Origin. |
| Dec 05 | DOE phenotyping contract | Positive | +0.4% | Four-year, up to $47M contract for high-throughput phenotyping platform. |
| Dec 03 | ARPA-H EMBODY support | Positive | +4.9% | Participation in STRM.BIO’s ARPA-H EMBODY-funded MV gene therapy program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent partnership and contract announcements have more often led to positive 1-day price reactions, with one notable divergence.
Over the last months, Ginkgo Bioworks reported several partnership and contract wins. On Dec 22, 2025, an ARPA-H backed cancer screening partnership with Carnegie Mellon saw shares rise 8.52%. Earlier in December, collaborations with Agricen, Deep Origin, and PNNL, including a contract of up to $47M, produced modest moves between -0.24% and 1.70%. Participation in today’s J.P. Morgan Healthcare Conference fits a pattern of ongoing business development and visibility-building announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-44th-annual-jp-morgan-healthcare-conference-302659475.html
SOURCE Ginkgo Bioworks